13/09/2024 Selexipag for treating pulmonary arterial hypertension
NRThe Ministry of Health’s Drug Advisory Committee has not recommended selexipag for inclusion on the MOH List of Subsidised Drugs as an add-on therapy for patients with pulmonary arterial hypertension who are insufficiently controlled with an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor. The decision was based on the unfavourable cost effectiveness of selexipag compared with placebo at the prices proposed by the company.